Is Lucid Diagnostics, Inc. overvalued or undervalued?

As of 13 November 2023, the valuation grade for Lucid Diagnostics, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company is currently considered overvalued based on its negative financial ratios, including a Price to Book Value of -25.96 and an EV to EBITDA of -3.16. Additionally, the Return on Capital Employed (ROCE) stands at a staggering -1564.48%, further highlighting the company's struggles.
In comparison to peers, Lucid Diagnostics has a P/E ratio of -2.8046, while Cardiff Oncology, Inc. is also classified as does not qualify with a P/E of -5.0384. In contrast, Pro-Dex, Inc. is rated very attractive with a P/E of 15.6736, illustrating a significant disparity in valuation among similar companies. Despite a strong year-to-date return of 45.35%, the overall financial metrics suggest that Lucid Diagnostics is not a sound investment at its current valuation.